{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bauman GS"],"funding":["Ontario Institute for Cancer Research","Internal funding, Department of Oncology, London Health Sciences Centre"],"pagination":["405"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8048078"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(1)"],"pubmed_abstract":["<h4>Background</h4>Patients with polymetastatic cancer are most often treated with systemic therapy to improve overall survival and/or delay progression, with palliative radiotherapy reserved for sites of symptomatic disease. Stereotactic ablative radiotherapy (SABR) has shown promise in the treatment of oligometastatic disease, but the utility of SABR in treating all sites of polymetastatic disease has yet to be evaluated. This study aims to evaluate the maximally tolerated dose (MTD) of SABR in patients with polymetastatic disease.<h4>Methods</h4>Up to 48 patients with polymetastatic cancer (> 10 sites) will be enrolled on this phase I, modified 3 + 3 design trial. Eligible patients will have exhausted (or refused) standard systemic therapy options. SABR will be delivered as an escalatin"],"journal":["BMC cancer"],"pubmed_title":["Ablative radiation therapy to restrain everything safely treatable (ARREST): study protocol for a phase I trial treating polymetastatic cancer with stereotactic radiotherapy."],"pmcid":["PMC8048078"],"funding_grant_id":["n/a"],"pubmed_authors":["Bauman GS","Corkum MT","Nguyen TK","Palma DA","Fakir H"],"additional_accession":[]},"is_claimable":false,"name":"Ablative radiation therapy to restrain everything safely treatable (ARREST): study protocol for a phase I trial treating polymetastatic cancer with stereotactic radiotherapy.","description":"<h4>Background</h4>Patients with polymetastatic cancer are most often treated with systemic therapy to improve overall survival and/or delay progression, with palliative radiotherapy reserved for sites of symptomatic disease. Stereotactic ablative radiotherapy (SABR) has shown promise in the treatment of oligometastatic disease, but the utility of SABR in treating all sites of polymetastatic disease has yet to be evaluated. This study aims to evaluate the maximally tolerated dose (MTD) of SABR in patients with polymetastatic disease.<h4>Methods</h4>Up to 48 patients with polymetastatic cancer (> 10 sites) will be enrolled on this phase I, modified 3 + 3 design trial. Eligible patients will have exhausted (or refused) standard systemic therapy options. SABR will be delivered as an escalatin","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2026-07-16T08:48:30.181Z","creation":"2022-02-09T16:05:23.365Z"},"accession":"S-EPMC8048078","cross_references":{"pubmed":["33853550"],"doi":["10.1186/s12885-021-08020-2"]}}